G ardasil, the vaccine that protects women from common strains of the human papillomavirus (HPV) responsible for about 70% of cervical cancers, has proved successful. According to the Centers for Disease Control and Prevention’s National Immunization Survey, about 25% of women have received the vaccine. Now Merck, the pharmaceutical giant that manufactures Gardasil, is looking to match that suc...

Human papillomavirus (HPV) can induce cervical intraepithelial neoplasia (CIN). Vaccination against HPV can play an important role in CIN prevention. This study aims to estimate the efficacy of L1 protein vaccines (Cervarix and Gardasil) in CIN 1, 2, 3 risk reduction using meta-analysis. Relevant articles were identified by two independent researchers searching international databanks. After ap...

938 Human Vaccines & Immunotherapeutics Volume 9 Issue 4 Table 1 in the article incorrectly identifies the isotype of monoclonal antibodies that are used in stability indicating assays that support the Gardasil product line. Corrections to Table 1, revised Feb 2012, correct 2 mAb isotype designation H16.J4 = IgG2a and H18. J4 = IgG2a, see corrected table below. Correction to: Smith JF, et al. H...

The authors describe the case of a 5-year-old girl with recurrent laryngeal papillomatosis (RLP) due to human papillomavirus (HPV) type 11, who required frequent surgical treatment. Complete recovery occurred after HPV vaccination (Gardasil). Confirmed remission of RLP has continued during the 17 months of follow-up since vaccination. The authors conclude that HPV vaccination may represent a ne...

Recent advances in the development of immunotherapeutic mAbs for cancer New vaccine reduces malaria infection by 72% Bavarian Nordic's cancer immunotherapy shows promise in colorectal cancer Chinese HFMD vaccine shows high efficacy in Phase 3 Two-dose regimen of Merck's Gardasil looks effective Accelerating influenza vaccine development using synthetic biology A key role for gut microbes in vac...

HPV vaccines are highly effective at preventing anogenital HPV infections and the neoplastic diseases that they cause (Herrero et al., 2015). Like other licensed anti-viral prophylactic vaccines, the HPV vaccines are thought to function primarily by inducing antibodies that bind the virus, thereby preventing infection (Schiller and Lowy, 2012). In the case of the three licensed HPV vaccines, th...

Cervical cancer, caused by Human Papillomavirus (HPV) is the third largest cause of female mortality over the world with an estimated 500,000 cases and 270,000 deaths annually [1]. Nevertheless there are only two vaccines are available in the world market to protect cervical cancer. Gardasil® (Merck, USA)) and Cervarix® (GlaxoSmithKline, UK) are both Virus Like Particle (VLP) based vaccines and...